LeonaBio, Inc. has 14 Schedule 13D or 13G filings on record since 2025-10-10. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Sermonix Pharmaceuticals, Inc. | 36.9% | 5,502,402 | SCHEDULE 13D, 2026-08-31 | 2026-08-24 |
| Perceptive Advisors LLC | 19.99% | 1,889,403 | SCHEDULE 13D/A, 2026-08-25 | 2026-08-22 |
| Anders Hove | 12.1% | 1,492,521 | SCHEDULE 13G/A, 2026-08-20 | 2026-08-18 |
| ADAR1 Capital Management, LLC | 7.7% | 727,481 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Oliveira Steven Michael | 4.09% | 161,218 | SCHEDULE 13G/A, 2025-10-10 | 2025-10-01 |
| Baselake Partners, LP | 1.9% | 75,789 | SCHEDULE 13G/A, 2026-02-06 | 2025-12-31 |
| BML Investment Partners, L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-12-18 | 2025-12-18 |
Purpose of Transaction (Item 4)
Perceptive Advisors LLC
Item 4 of the Schedule 13D is amended and supplemented as follows: On August 22, 2026, Sermonix notified the Reporting Persons that it will distribute Sermonix Pre-Funded Warrants exercisable for 2,352,932 shares of Common Stock to PXV II pursuant to a distribution of securities to owners of Sermonix's common stock. The distribution is expected to be effective on October 26, 2026. Pursuant to the terms of the Sermonix Pre-Funded Warrants, the pre-funded warrants that will be held by PXV II will not be exerciseable to the extent that such exercise would result in beneficial ownership in excess of 19.99% of the outstanding shares of Common Stock of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2026-08-25
Sermonix Pharmaceuticals, Inc.
The acquisition of securities of the issuer is part of a strategic collaboration as previously disclosed between Sermonix Pharmaceuticals, Inc. and the Issuer, as set forth in the previously disclosed License Agreement and Securities Purchase Agreement.Item 4 of the SCHEDULE 13D filed 2026-08-31
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-10 | Oliveira Steven Michael | 4.09% | SCHEDULE 13G/A |
| 2025-11-14 | Baselake Partners, LP | 5% | SCHEDULE 13G |
| 2025-12-18 | BML Investment Partners, L.P. | 0% | SCHEDULE 13G/A |
| 2025-12-22 | Perceptive Advisors LLC | 13.9% | SCHEDULE 13D/A |
| 2025-12-23 | Perceptive Advisors LLC | 20.1% | SCHEDULE 13D/A |
| 2025-12-23 | Anders Hove | 5.2% | SCHEDULE 13G |
| 2026-01-08 | Anders Hove | 6.2% | SCHEDULE 13G/A |
| 2026-01-16 | Perceptive Advisors LLC | 19.99% | SCHEDULE 13D/A |
| 2026-02-06 | Baselake Partners, LP | 1.9% | SCHEDULE 13G/A |
| 2026-05-07 | Perceptive Advisors LLC | 19.99% | SCHEDULE 13D/A |
| 2026-05-15 | ADAR1 Capital Management, LLC | 7.7% | SCHEDULE 13G |
| 2026-08-20 | Anders Hove | 12.1% | SCHEDULE 13G/A |
| 2026-08-25 | Perceptive Advisors LLC | 19.99% | SCHEDULE 13D/A |
| 2026-08-31 | Sermonix Pharmaceuticals, Inc. | 36.9% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for LeonaBio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.